RMD
Resmed IncTrades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-07 | Farrell Michael J. |
Director, Chairman and CEO |
Convert↓
Filing footnotes — ResMed Common Stock Options (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Represents date options first become exercisable. Options vest 1/3 per year. |
ResMed Common Stock Options
|
4,991 |
| 2026-07-07 | Farrell Michael J. |
Director, Chairman and CEO |
Sell↓
Filing footnotes — ResMed Common Stock (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. This transaction was executed in multiple trades at prices ranging from $216.772 - $219.700. The price reported above reflects the weighted average sale price. |
ResMed Common Stock
|
4,991 |
| 2026-07-07 | Farrell Michael J. |
Director, Chairman and CEO |
Convert↑
Filing footnotes — ResMed Common Stock (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. |
ResMed Common Stock
|
4,991 |
| 2026-06-08 | Farrell Michael J. |
Director, Chairman and CEO |
Sell↓
Filing footnotes — ResMed Common Stock (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. This transaction was executed in multiple trades at prices ranging from $192.605 - $194.715. The price reported above reflects the weighted average sale price. Includes 32.671 shares of Resmed stock purchased on April 30, 2026 through the Resmed Employee Stock Purchase Plan. |
ResMed Common Stock
|
4,991 |
| 2026-06-08 | Farrell Michael J. |
Director, Chairman and CEO |
Convert↓
|
ResMed Common Stock Options
|
4,991 |
| 2026-06-08 | Farrell Michael J. |
Director, Chairman and CEO |
Convert↑
Filing footnotes — ResMed Common Stock (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. |
ResMed Common Stock
|
4,991 |
| 2026-06-01 | Rider Michael J |
Global General Counsel |
Tax↓
Filing footnotes — ResMed Common Stock (Direct)
Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 06/01/2023. Includes 66.0288 shares of Resmed stock purchased on April 30, 2026 through the Resmed Employee Stock Purchase Plan. |
ResMed Common Stock
|
268 |
| 2026-05-07 | Farrell Michael J. |
Director, Chairman and CEO |
Convert↓
Filing footnotes — ResMed Common Stock Options (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Represents date options first become exercisable. Options vest 1/3 per year. |
ResMed Common Stock Options
|
4,991 |
| 2026-05-07 | Farrell Michael J. |
Director, Chairman and CEO |
Convert↑
Filing footnotes — ResMed Common Stock (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. |
ResMed Common Stock
|
4,991 |
| 2026-05-07 | Farrell Michael J. |
Director, Chairman and CEO |
Sell↓
Filing footnotes — ResMed Common Stock (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. This transaction was executed in multiple trades at prices ranging from $206.45 - $210.47. The price reported above reflects the weighted average sale price. |
ResMed Common Stock
|
4,991 |
| 2026-05-04 | Bloomer Aaron |
EVP, Chief Financial Officer |
Other↑
|
No Securities Owned
|
0 |
| 2026-04-07 | Farrell Michael J. |
Director, Chairman and CEO |
Convert↓
Filing footnotes — ResMed Common Stock Options (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Represents date options first become exercisable. Options vest 1/3 per year. |
ResMed Common Stock Options
|
4,991 |
| 2026-04-07 | Farrell Michael J. |
Director, Chairman and CEO |
Convert↑
Filing footnotes — ResMed Common Stock (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. |
ResMed Common Stock
|
4,991 |
| 2026-04-07 | Farrell Michael J. |
Director, Chairman and CEO |
Sell↓
Filing footnotes — ResMed Common Stock (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. This transaction was executed in multiple trades at prices ranging from $222.5643 - $227.96. The price reported above reflects the weighted average sale price. |
ResMed Common Stock
|
4,991 |
| 2026-04-01 | FARRELL PETER C |
Director |
Sell↓
Filing footnotes — ResMed Common Stock (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025. |
ResMed Common Stock
|
2,000 |
| 2026-04-01 | Sandercock Brett |
Chief Financial Officer |
Sell↓
Filing footnotes — ResMed Common Stock (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. |
ResMed Common Stock
|
1,000 |
| 2026-03-09 | Farrell Michael J. |
Director, Chairman and CEO |
Convert↓
Filing footnotes — ResMed Common Stock Options (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Represents date options first become exercisable. Options vest 1/3 per year. |
ResMed Common Stock Options
|
4,991 |
| 2026-03-09 | Farrell Michael J. |
Director, Chairman and CEO |
Convert↑
Filing footnotes — ResMed Common Stock (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. |
ResMed Common Stock
|
4,991 |
| 2026-03-09 | Farrell Michael J. |
Director, Chairman and CEO |
Sell↓
Filing footnotes — ResMed Common Stock (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. This transaction was executed in multiple trades at prices ranging from $246.83 - $253.09. The price reported above reflects the weighted average sale price. |
ResMed Common Stock
|
4,991 |
| 2026-03-04 | FARRELL PETER C |
Director |
Sell↓
Filing footnotes — ResMed Common Stock (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025. |
ResMed Common Stock
|
2,000 |
| 2026-03-02 | Sandercock Brett |
Chief Financial Officer |
Sell↓
Filing footnotes — ResMed Common Stock (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. |
ResMed Common Stock
|
1,000 |
| 2026-02-09 | Farrell Michael J. |
Director, Chairman and CEO |
Convert↓
Filing footnotes — ResMed Common Stock Options (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Represents date options first become exercisable. Options vest 1/3 per year. |
ResMed Common Stock Options
|
4,991 |
| 2026-02-09 | Farrell Michael J. |
Director, Chairman and CEO |
Sell↓
Filing footnotes — ResMed Common Stock (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. This transaction was executed in multiple trades at prices ranging from $270.25 - $276.35. The price reported above reflects the weighted average sale price. |
ResMed Common Stock
|
4,991 |
| 2026-02-09 | Farrell Michael J. |
Director, Chairman and CEO |
Convert↑
Filing footnotes — ResMed Common Stock (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. |
ResMed Common Stock
|
4,991 |
| 2026-02-04 | FARRELL PETER C |
Director |
Sell↓
Filing footnotes — ResMed Common Stock (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025. |
ResMed Common Stock
|
2,000 |
| 2026-02-04 | Rider Michael J |
Global General Counsel |
Sell↓
Filing footnotes — ResMed Common Stock (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted February 28, 2025. |
ResMed Common Stock
|
50 |
| 2026-02-02 | Sandercock Brett |
Chief Financial Officer |
Sell↓
Filing footnotes — ResMed Common Stock (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. |
ResMed Common Stock
|
1,000 |
| 2026-01-07 | Farrell Michael J. |
Director, Chairman and CEO |
Convert↑
Filing footnotes — ResMed Common Stock (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. |
ResMed Common Stock
|
4,991 |
| 2026-01-07 | Farrell Michael J. |
Director, Chairman and CEO |
Convert↓
Filing footnotes — ResMed Common Stock Options (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Represents date options first become exercisable. Options vest 1/3 per year. |
ResMed Common Stock Options
|
4,991 |
| 2026-01-07 | Farrell Michael J. |
Director, Chairman and CEO |
Sell↓
Filing footnotes — ResMed Common Stock (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. This transaction was executed in multiple trades at prices ranging from $246.801 - $249.969. The price reported above reflects the weighted average sale price. |
ResMed Common Stock
|
4,991 |
| 2026-01-07 | FARRELL PETER C |
Director |
Sell↓
Filing footnotes — ResMed Common Stock (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025. |
ResMed Common Stock
|
2,000 |
| 2026-01-02 | Sandercock Brett |
Chief Financial Officer |
Sell↓
Filing footnotes — ResMed Common Stock (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. |
ResMed Common Stock
|
1,000 |
| 2026-01-02 | Rider Michael J |
Global General Counsel |
Sell↓
Filing footnotes — ResMed Common Stock (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted February 28, 2025. |
ResMed Common Stock
|
50 |
| 2025-12-08 | Farrell Michael J. |
Director, Chairman and CEO |
Sell↓
Filing footnotes — ResMed Common Stock (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. This transaction was executed in multiple trades at prices ranging from $249.63 - $255.775. The price reported above reflects the weighted average sale price. |
ResMed Common Stock
|
4,991 |
| 2025-12-08 | Farrell Michael J. |
Director, Chairman and CEO |
Convert↑
Filing footnotes — ResMed Common Stock (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. |
ResMed Common Stock
|
4,991 |
| 2025-12-08 | Farrell Michael J. |
Director, Chairman and CEO |
Convert↓
Filing footnotes — ResMed Common Stock Options (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Represents date options first become exercisable. Options vest 1/3 per year. |
ResMed Common Stock Options
|
4,991 |
| 2025-12-03 | FARRELL PETER C |
Director |
Sell↓
Filing footnotes — ResMed Common Stock (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025. |
ResMed Common Stock
|
2,000 |
| 2025-12-01 | Rider Michael J |
Global General Counsel |
Sell↓
Filing footnotes — ResMed Common Stock (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted February 28, 2025. |
ResMed Common Stock
|
50 |
| 2025-12-01 | Sandercock Brett |
Chief Financial Officer |
Sell↓
Filing footnotes — ResMed Common Stock (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. |
ResMed Common Stock
|
1,000 |
| 2025-11-25 | De Witte Jan |
Director |
Sell↓
Filing footnotes — ReMed Common Stock (Direct)
The transaction was conducted under a Rule 10b5-1 plan adopted on August 18, 2025. |
ReMed Common Stock
|
2,055 |
| 2025-11-24 | Mowad-Nassar Nicole |
Director |
Award↑
Filing footnotes — ResMed Common Stock Options (Direct)
Represents the date on which options first become exercisable. The options vest on the earlier of (i) November 11, 2026, or (ii) the date of the first annual meeting of stockholders of the Company following the Grant Date. |
ResMed Common Stock Options
|
1,331 |
| 2025-11-24 | FARRELL PETER C |
Director |
Award↑
Filing footnotes — ResMed Common Stock Options (Direct)
Represents the date on which options first become exercisable. The options vest on the earlier of (i) November 11, 2026, or (ii) the date of the first annual meeting of stockholders of the Company following the Grant Date. |
ResMed Common Stock Options
|
1,331 |
| 2025-11-24 | Farrell Michael J. |
Director, Chairman and CEO |
Award↑
Filing footnotes — ResMed Common Stock Options (Direct)
Represents the date on which options first become exercisable. The options vest in three equal annual installments commencing on November 11, 2026. |
ResMed Common Stock Options
|
33,288 |
| 2025-11-20 | TAYLOR RONALD R |
Director |
Award↑
Filing footnotes — ResMed Common Stock (Direct)
Shares awarded represent Restricted Stock Units. The RSUs vest in full on the earlier of 11/11/2026, or the annual meeting of stockholders in the year following the grant date. |
ResMed Common Stock
|
1,073 |
| 2025-11-20 | FARRELL PETER C |
Director |
Award↑
Filing footnotes — ResMed Common Stock (Direct)
Shares awarded represent Restricted Stock Units. The RSUs vest in full on the earlier of 11/11/2026, or the annual meeting of stockholders in the year following the grant date. |
ResMed Common Stock
|
536 |
| 2025-11-20 | Burt Carol |
Director |
Award↑
Filing footnotes — ResMed Common Stock (Direct)
Shares awarded represent Restricted Stock Units. The RSUs vest in full on the earlier of 11/11/2026, or the annual meeting of stockholders in the year following the grant date. |
ResMed Common Stock
|
1,073 |
| 2025-11-20 | Drexler Karen |
Director |
Award↑
Filing footnotes — ResMed Common Stock (Direct)
Shares awarded represent Restricted Stock Units. The RSUs vest in full on the earlier of 11/11/2026, or the annual meeting of stockholders in the year following the grant date. |
ResMed Common Stock
|
1,073 |
| 2025-11-20 | DelOrefice Christopher |
Chief Financial Officer |
Award↑
Filing footnotes — ResMed Common Stock (Direct)
Shares awarded represent Restricted Stock Units. The RSUs vest in full on the earlier of 11/11/2026, or the annual meeting of stockholders in the year following the grant date. |
ResMed Common Stock
|
1,073 |
| 2025-11-20 | Farrell Michael J. |
Director, Chairman and CEO |
Award↑
Filing footnotes — ResMed Common Stock (Direct)
Represents performance-based restricted stock units granted on November 16, 2022. The shares were earned on November 20, 2025, when the compensation and leadership development committee certified that the performance metrics were met. |
ResMed Common Stock
|
13,551 |
| 2025-11-20 | Gill Harjit |
Director |
Award↑
Filing footnotes — ResMed Common Stock (Direct)
Shares awarded represent Restricted Stock Units. The RSUs vest in full on the earlier of 11/11/2026, or the annual meeting of stockholders in the year following the grant date. |
ResMed Common Stock
|
1,073 |